Compare Invesco NASDAQ 100 ETF (QQQM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Viatris Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $290.09, while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while Invesco NASDAQ 100 ETF pays none, and Viatris Inc is trading nearer its 52-week high, Invesco NASDAQ 100 ETF nearer its low. Which is the better fit depends on your goals.
| QQQM | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $17.59 |
52-Week Low | $228.02 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
